SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2020 , Vol. 40 >Issue 8: 2450 - 2459

DOI: https://doi.org/10.6023/cjoc201910037

Design, Synthesis, and Biological Activities of Novel Triazolothiadiazole Derivatives Linked with Amino Side Chain Containing Urea Group as DOT1L Inhibitors

  • Liu Na ,
  • Guo Siqi ,
  • Liu Junfang ,
  • Chen Yantao ,
  • Xu Xiaoming ,
  • Zhang Jing ,
  • Kang Yaqing ,
  • Luo Cheng ,
  • Chen Shijie ,
  • Chen Hua
Expand
  • a Key Laboratory of Chemical Biology of Hebei Province, College of Chemistry and Environmental Science, Hebei University, Baoding, Hebei 071002;
    b State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203;
    c School of Pharmacy, Nanchang University, Nanchang 330006

Received date: 2019-10-29

  Revised date: 2020-01-13

  Online published: 2020-05-28

Supported by

Project supported by the Natural Science Interdisciplinary Research Program of Hebei University (No. DXK201903).

Fold

Abstract

Based on the drug design method of combination of privileged fragments, a series of novel triazolothiadiazole derivatives linked with amino side chain containing urea group were designed as potential DOT1L (disruptor of telomeric silencing 1-like) inhibitors. The intermediate 13 with benzyl chloride on triazolothiadiazole structure was synthesized from aromatic acid through five steps. Under the condition of weak base (DIPEA), the nucleophilic substitution reaction between 13 and amino chain with urea group resulted in triazolothiadiazole derivatives linked with amino side chain containing urea group 15a~15k, while under the condition of strong base (NaH), the new dimeric structure analogues 22a~22d bearing with triazolothiadiazole-triazolothiadiazine were obtained by intermolecular reaction of two molecules of 13. The inhibitory activities of compounds 15 and 22 against DOT1L were tested. The results showed that the tested compounds exhibited moderate or weak DOT1L inhibitory activities at 50 μmol·L-1. Among them, compounds 15k and 22a were the best ones with IC50 values of 25.92 and 10.59 μmol·L-1, respectively, lower than that of the positive control (E)-6-(2-(furan-2-yl)vinyl)-3-phenyl-[1,2, 4]triazolo[3,4-b] [1,3,4]thiadiazole (10). The results of docking experiments suggested that the bulky amino-urea side chain might be the main reason for the loss of the activities of the compounds, which sterically hindered the molecular from binding to the DOT1L enzyme.

Key words： DOT1L inhibitor; triazolothiadiazole; triazolothiadiazine; nucleophilic substitution

Cite this article

Liu Na , Guo Siqi , Liu Junfang , Chen Yantao , Xu Xiaoming , Zhang Jing , Kang Yaqing , Luo Cheng , Chen Shijie , Chen Hua . Design, Synthesis, and Biological Activities of Novel Triazolothiadiazole Derivatives Linked with Amino Side Chain Containing Urea Group as DOT1L Inhibitors[J]. Chinese Journal of Organic Chemistry, 2020 , 40(8) : 2450 -2459 . DOI: 10.6023/cjoc201910037

References

[1] Min, J. R.; Feng, Q.; Li, Z. Z.; Zhang, Y.; Xu, R. M. Cell 2003, 112, 711.
[2] Kim, W.; Choi, M.; Kim, J. E. Cell Cycle 2014, 13, 726.
[3] Bernt, K. M.; Zhu, N.; Sinha, A. U.; Vempati, S.; Faber, J.; Krivtsov, A. V.; Feng, Z.; Punt, N.; Daigle, A.; Bullinger, L.; Pollock, R. M.; Richon, V. M.; Kung, A. L.; Armstrong, S. A. Cancer Cell 2011, 20, 66.
[4] Lillico, R.; Lawrence, C. K. Lakowski, T. M. J. Proteome Res. 2018, 17, 2657.
[5] Anglin, J. L.; Song, Y. J. Med. Chem. 2013, 56, 8972.
[6] Zhou, S. H.; Sun, P. J.; Zhao, Y. Q.; Zhang, Y.; Yu, N. F. Acta Pharm. Sin. 2018, 53, 500(in Chinese). (周仕海, 孙朋举, 赵勇强, 张岩, 余聂芳, 药学学报, 2018, 53, 500.)
[7] Ümit Kaniskan, H.; Martini, M. L.; Jin, J. Chem. Rev. 2018, 118, 989.
[8] Basavapathruni, A.; Jin, L.; Daigle, S. R.; Majer, C. R.; Therkelsen, C. A.; Wigle, T. J.; Kuntz, K. W.; Chesworth, R.; Pollock, R. M.; Scott, M. P. Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Olhava, E. J. Chem. Biol. Drug Des. 2012, 80, 971.
[9] Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.; Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.; Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K. M.; Tseng, J. C.; Kung, A. L.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Cancer Cell 2011, 20, 53.
[10] Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Savona, M.; Tibes, R.; Altman, J. K.; Jongen-Lavrencic, M.; Dohner, H.; Armstrong, S.; Pollock, R. M.; Waters, N. J.; Legler, M.; Thomson, B.; Daigle, S.; McDonald, A.; Campbell, C.; Olhava, E.; Hedrick, E. E.; Lowenberg, B.; Copeland, R. A.; Tallman, M. S. Blood 2014, 124, 387.
[11] Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.; Prasad, B. V.; Song, Y. J. Am. Chem. Soc. 2011, 133, 16746.
[12] Anglin, J. L.; Deng, L.; Yao, Y.; Cai, G.; Liu, Z.; Jiang, H.; Cheng, G.; Chen, P.; Dong, S.; Song, Y. J. Med. Chem. 2012, 55, 8066.
[13] Yu, W.; Chory, E. J.; Wernimont, A. K.; Tempel, W.; Scopton, A.; Federation, A.; Marineau, J. J.; Qi, J.; Barsyte-Lovejoy, D.; Yi, J.; Marcellus, R.; Iacob, R. E.; Engen, J. R.; Griffin, C.; Aman, A.; Wienholds, E.; Li, F.; Pineda, J.; Estiu, G.; Shatseva, T.; Hajian, T.; Al-Awar, R.; Dick, J. E.; Vedadi, M.; Brown, P. J.; Arrowsmith, C. H.; Bradner, J. E.; Schapira, M. Nat. Commun. 2012, 3, 1288.
[14] Yu, W.; Smil, D.; Li, F.; Tempel, W.; Fedorov, O.; Nguyen, K. T.; Bolshan, Y.; Al-Awar, R.; Knapp, S.; Arrowsmith, C. H.; Vedadi, M.; Brown, P. J.; Schapira, M. Bioorg. Med. Chem. 2013, 21, 1787.
[15] Spurr, S. S.; Bayle, E. D.; Yu, W. Y.; Li, F. L.; Tempel, W.; Vedadi, M.; Schapira, M.; Fish, P. V. Bioorg. Med. Chem. Lett. 2016, 26, 4518.
[16] Chen, J.; Park, H. J. ACS Chem. Biol. 2019, 14, 873.
[17] Scheufler, C.; Möbitz, H.; Gaul, C.; Ragot, C.; Be, C.; Fernández, C.; Beyer, K. M.; Tiedt, R.; Stauffer, F. ACS Med. Chem. Lett. 2016, 7, 730.
[18] Chao, C.; Zhu, H.; Stauffer, F.; Caravatti, G.; Vollmer, S.; Machauer, R.; Holzer, P.; Möbitz, H.; Scheufler, C.; Klumpp, M.; Tiedt, R.; Beyer, K. S.; Calkins, K.; Guthy, D.; Kiffe, M.; Zhang, J.; Gaul, C. ACS Med. Chem. Lett. 2016, 7, 735.
[19] Möbitz, H.; Machauer, R.; Holzer, P.; Vaupel, A.; Stauffer, F.; Ragot, C.; Caravatti, G.; Scheufler, C.; Fernández, C.; Hommel, U.; Tiedt, R.; Beyer, K. S.; Chao, C.; Zhu, H.; Gaul, C. ACS Med. Chem. Lett. 2017, 8, 338.
[20] Chen, S. J.; Wang, Y. L.; Zhou, W.; Li, S. S.; Peng, J. L.; Shi, Z.; Hu, J. C.; Liu, Y. C.; Ding, H.; Lin, Y. Y.; Li, L. J.; Cheng, S. F.; Liu, J. Q.; Lu, T.; Jiang, H. L.; Liu, B.; Zheng, M. Y.; Luo, C. J. Med. Chem. 2014, 57, 9028.
[21] Chen, S.; Li, L.; Chen, Y.; Hu, J.; Liu, J.; Liu, Y. C.; Liu, R.; Zhang, Y.; Meng, F.; Zhu, K.; Lu, J.; Zheng, M.; Chen, K.; Zhang, J.; Jiang, H.; Yao, Z.; Luo, C. J. Chem. Inf. Model. 2016, 56, 527.
[22] Wang, Y. L.; Li, L. J.; Zhang, B. D.; Xing, J.; Chen, S. J.; Wan, W.; Song, Y. K.; Jiang, H.; Jiang, H. L.; Luo, C.; Zheng, M. Y. J. Med. Chem. 2017, 60, 2026.
[23] Song, Y. K.; Li, L. J.; Chen, Y. T.; Liu, J. Q.; Xiao, S. H.; Lian, F. L.; Zhang, N. X.; Ding, H.; Zhang, Y. Y.; Chen, K. X.; Jiang, H. L.; Zhang, C. H.; Liu, Y. C.; Chen, S. J.; Luo, C. Bioorg. Med. Chem. 2018, 26, 1751.
[24] Zhang, L.; Chen, Y. T.; Liu, N.; Li, L. J.; Xiao, S. H.; Li, X. L.; Chen, K. X.; Luo, C.; Chen, S. J.; Chen, H. Bioorg. Chem. 2018, 80, 649.
[25] Cui, P. L.; Li, X. L.; Zhu, M. Y.; Wang, B. H.; Liu, J.; Chen, H. Eur. J. Med. Chem. 2017, 127, 159.
[26] Maestro, Version 10.4, Schrödinger, LLC, New York, 2015.
[27] Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739.
[28] Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. J. Med. Chem. 2006, 49, 6177.
[29] Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Thomas Pollard, W.; Banks, J. L. J. Med. Chem. 2004, 47, 1750.
[30] Glide, Version 6.9, Schrödinger, LLC, New York, 2015.
Options
Outlines

/

〈 〉